|Dr. Adi Hoess||CEO, MD & Member of Management Board||754.87k||N/A||1961|
|Dr. Wolfgang Fischer||MD, COO & Member of Management Board||605.09k||N/A||1964|
|Prof. Melvyn Little||Founder & Consultant||N/A||N/A||N/A|
|Mr. Angus W. Smith||Chief Financial Officer||N/A||N/A||1982|
|Dr. Arndt J. G. Schottelius||Chief Scientific Officer||N/A||N/A||1966|
|Mr. Michael Wolf||Head of Fin. & Admin.||N/A||N/A||1967|
|Mr. Alexander Fudukidis||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Uwe Reusch||Head of Cell Culture||N/A||N/A||N/A|
|Dr. Stefan Knackmuss||Head of Antibody Screening||N/A||N/A||N/A|
|Dr. Sergey Kipriyanov||Head of R&D||N/A||N/A||N/A|
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Affimed N.V.’s ISS Governance QualityScore as of April 1, 2021 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 9; Compensation: 8.